Product Description
Cigna Qingdao is mainly engaged in the intermediates of febuxostatin, ceflothrin, eprazole, flubiprofen, phenalidone, tovaptan, rivaroxaban and Avanafil, terbinafine intermediates, thioacetamide and thiophene and their derivatives.
AI Product Description
*The following content is generated by AI and is for reference only.
tBuO-Ste-Glu(AEEA-AEEA-OH)OtBu is a sophisticated PEGylated amino acid derivative designed primarily for the synthesis of complex polyethylene glycol (PEG)-based pharmaceutical conjugates and bioconjugates. This compound serves as a critical linker in the development of antibody-drug conjugates (ADCs), peptide therapeutics, and protein-polymer hybrids. The molecule features a central glutamic acid residue functionalized with two distinct protecting groups: tert-butyl esters at both the N-terminus and C-terminus, which provide stability during solid-phase synthesis while allowing selective deprotection under acidic conditions.
The core structural innovation lies in the AEEA (aminoethoxyacetic acid) spacer units. These two repeating AEEA segments act as flexible hydrophilic linkers that bridge the stearyl moiety (Ste) to the glutamic acid backbone. The stearyl group introduces lipophilicity, facilitating membrane interaction or anchoring within lipid bilayers, making this reagent ideal for creating amphiphilic constructs used in drug delivery systems. The terminal hydroxyl group on the distal end offers a versatile handle for further conjugation reactions, enabling the attachment of various payloads such as cytotoxic drugs, fluorophores, or targeting ligands.
In terms of chemical specifications, this product typically appears as a white to off-white powder, soluble in common organic solvents like dimethyl sulfoxide (DMSO), dichloromethane, and methanol. While specific CAS registry numbers for highly customized PEG-linker variants can vary based on exact purity grades and manufacturer batches, it generally falls under specialized chemical intermediates rather than standard commercial commodities. Researchers utilize tBuO-Ste-Glu(AEEA-AEEA-OH)OtBu to optimize the pharmacokinetic profiles of therapeutic agents. By modulating the length and composition of the PEG-like spacer, scientists can significantly enhance the solubility, circulation half-life, and reduced immunogenicity of the final bioconjugate without compromising its biological activity. Its robust protection strategy ensures high yield and purity during automated synthesis processes, making it an indispensable tool in modern medicinal chemistry and biopharmaceutical manufacturing for next-generation targeted therapies.